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In industrialized countries there has been a significant increase in life expectancy, but chronic
diseases are still important causes of death and disability in the elderly. Individuals over
65 years of age have a decrease in organic functions and lungs can lose more than 40% of their
capacity.
Although asthma and allergic rhinitis are more common in young people their prevalence in
the elderly is increasing and the mortality reported in these patients is high.
Asthmatic airways show an accumulation of activated eosinophils and lymphocytes deter-
mining structural changes of the bronchi. Local allergic inflammation, changes in T cell pheno-
types and in apoptosis contribute to systemic inflammation. An increased risk of respiratory
infections and neoplasic diseases has been recognized.
These patients have increased susceptibility to atherosclerosis and cardiovascular diseases.
Metabolic diseases are associated with an impairment of lung function and with systemic
inflammation. Summing up older asthmatic patients have an increased risk to premature
disability and death.
A proper therapeutic approach to asthma can minimize this evolution. To identify the trig-
gers is an important goal that allows reducing medication needs. Corticosteroids dampen
allergic inflammation; therefore, they are the first choice in the treatment of patients with
persistent asthma and rhinitis. Second-generation H1 receptor antagonists have reduced side
effects and can be used if necessary.
The elderly may have difficult access to health care. They should be educated about their
disease and receive a written treatment plan. This information improves the quality of life,
socialization and disease outcome in older people.
ª 2009 Elsevier Ltd. All rights reserved.351 239822547.
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In industrialized countries the significant increase in life
expectancy and the declining fertility rates are shifting the
age distribution of populations towards the older age
groups. Citizens over the age of 65 years account for more
than 20% of the European population. The increase in life
expectancy is partially due to substantial elimination of
infectious diseases through a better hygiene and a wide-
spread use of antibiotics and vaccines. Chronic diseases
such as cardiovascular diseases, stroke and cancer still
present unmet needs and are the main causes of death in
the elderly. Several additional chronic disorders, nutri-
tional disorders and stress contribute to the severity and to
the high mortality of the reported diseases. To find out the
right answers for health needs, autonomy and successful
ageing it is necessary to control the multiple chronic
conditions of the elderly.
Ageing is not a disease and this fact is central to
understanding the fundamental physiologic changes that
develop with age. Failure to distinguish between research
on ageing and research on age-associated diseases has been
the source of many misunderstandings.1 In the minds of
many biomedical scientists, no one suffers or dies from
ageing. People suffer and die from the diseases associated
with the ageing process. Death is a result of the inevitable
increase in systemic molecular distress that a long living
incurs, which enhances vulnerability to severe diseases.
The human ageing process affects multiple organs and
tissues and involves the progressive deterioration of all
body functions.2 Ageing is not only a programmed process
governed directly by genes, but also a stochastic process
that occurs after reproductive maturation, which results
from the decreased capacity to maintain molecular
homeostasis (Fig. 1).
Free radicals and oxidants, commonly called reactive
oxygen species (ROS), are highly reactive molecules that can
damage all sorts of cellular components inducing disease. ROS
can be originated from exogenous sources and from several
intracellular sources throughout chronic inflammatory
processes. Since oxidative damage of many cell types accu-
mulate with age, the free radical theory of ageing argues that
ageing results from the damage generated by ROS. To protect
against oxidation there are many different types of antioxi-
dants, such as Vitamins C and E as well as enzymes such assuperoxide dismutase (SOD), catalase and glutathione
peroxidase.3 Briefly, antioxidant enzymes are capable of
degrading ROS into inert compounds through several chemical
reactions. Some enzymes are also involved in the repair of
oxidative damaged biomolecules. Methionine sulfoxide
reductase A catalyzes the restore of protein-bound methio-
nine residues to methionine repairing the damaged proteins
oxidized by ROS.
The simple existence of enzymes to prevent and repair
damage by ROS is a strong indicator that ROS are dangerous
molecules with an important biological role in disease.4 The
inefficiency in the response of the antioxidant system can
result in an increase of oxidative stress, leading to oxidative
damage of biomolecules such as DNA, proteins and lipids.
Ageing of respiratory system
Individuals over 65 years of age even with a healthy life
style have a decrease in several organic functions. The
lungs can lose more than 40% of their capacity over time.5
Physiologic changes of the lungs due to ageing are charac-
terized by airspace enlargement without alveolar destruc-
tion, decrease in gas exchange surface and loss of
supporting tissue in the peripheral airways. These changes
result in decreased static elastic recoil of the lung,
increased residual volume and increased functional residual
capacity. Compliance of the chest wall diminishes and the
work of breathing increases. As people become older, the
respiratory muscles tend to be become weaker and this
change is directly correlated with individual nutritional
status. The decrease in expiratory flow rates produces
a characteristic alteration in the flow-volume curve typical
of small airways’ disease. The ventilationeperfusion ratio
heterogeneity increases as a consequence of premature
closing of the distal airways. Cough, that also helps to clear
the lungs, tends to be less effective. Nevertheless, in
healthy individuals, the respiratory system is capable of
keeping an adequate gas exchange during the entire life-
span, only with a slight decrease in arterial oxygen tension.
With ageing there are alterations in the pulmonary
performance and in the perception of breathing associated
to airway constriction as a consequence of a decline in the
sensitivity of the lung receptors.6
The decreased sensitivity of respiratory centers to
hypoxia can affect the response to airway obstruction. In
Figure 1 Molecular and cellular mechanisms associated with aging.
1616 A. Todo Bom, A. Mota Pintoaddition, decreased perception of dyspnoea may result in
lower awareness of respiratory diseases and delay in its
diagnosis.7
Ageing and respiratory allergy
Although asthma and allergic rhinitis are more frequent in
young people, they affect individuals of all ages. Both
asthma and rhinitis have a severe impact on patients’
quality of life in different domains.
Asthma is a chronic inflammatory disorder of the
airways, characterized by a widespread but variable bron-
chial obstruction and by hyper-responsiveness to several
triggers. Allergic rhinitis (AR) is a disorder of the upper
airways resulting from IgE-mediated inflammation of the
nose upon contact of the nasal mucosa with allergens. This
disease, also called allergic rhinosinusitis since histopath-
ologic changes also affect the paranasal sinuses, typically
presents with sneezing, nasal pruritus and obstruction. It is
often associated with allergic conjunctivitis. Approximately
75% of patients with asthma also have rhinosinusitis, which
in turn is a risk factor for asthma. Both diseases share
environmental and genetic risk factors. Treatment of upper
airway disease can improve asthma symptoms and decrease
lower airway hyper-responsiveness.8
The prevalence of respiratory allergic diseases in the
elderly is increasing and mortality rates are highest among
patients over 65 years old with asthma.9
The evolution of asthma and the limitation to the airway
flow depend on the additional effect of localized inflam-
matory process, airway remodeling and smooth muscle
contraction.10 Although dyspnoea, chest tightness, cough,
and wheezing that characterize asthma in young people
are also present in the elderly, an accurate differential
diagnosis with chronic obstructive pulmonary disease,congestive heart failure, ischemic heart disease, gastro-
esophageal reflux, pulmonary embolia, recurrent aspira-
tion, lung tumors, and laryngeal dysfunction should be
considered. Drug intake should also be carefully evaluated.
Most of the elderly patients have moderate asthma
despite long disease evolution and only about 20% of the
patients have severe asthma. Asthmatic patients tend to
develop a progressive decline in pulmonary function
dependent on age and asthma’s duration. However, asth-
matics may preserve normal lung function. The poorer
prognosis and higher death rates of asthma in older patients
are probably associated with chronic systemic inflammation
and recurrent exacerbations characteristic of the
disease.11,12 More than half of elderly patients with rhinitis
have persistent moderate-severe rhinitis.13
Some studies suggest that sensitization to indoor aller-
gens in the elderly may have a more relevant implication in
asthma than previously thought. The majority of elderly
allergic patients have specific IgE antibodies to indoor
allergens and only some of them present positive responses
to outdoor allergens in agreement with their higher expo-
sure to indoor allergens. In fact, older patients tend to
spend most of their time indoors. Nearly all subjects have
positive responses to house dust mite allergen extracts
while sensitization to pets is less common.14,15 The outdoor
allergens to which subjects are more often sensitized to are
grass pollen in Europe and ragweed in United States of
America. Most of these allergic patients suffer exacerbation
of their respiratory symptoms during spring or late summer
and fall according to their living area.16,17
Immuno-inflammatory changes in airways
In allergic respiratory diseases, airways’ and systemic
inflammation are triggered by repeated contact with
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multiple IgE antibodies that are bound to mast cells or
basophils. Released mediators promote the recruitment
and activation of eosinophils and lymphocytes and amplify
inflammatory response and symptoms. The significant
relationship established between IgE values or allergic
reactivity to common allergens and duration of disease in
people older than 65 years of age reinforces the concept
that respiratory allergy is present in the elderly.18 Allergens
are transported by airborne particles reaching mucosal
surfaces of the airways through inhalation. Upon initial
exposure to an allergen, specific Th2 cells are activated and
they stimulate B cells to secrete specific IgE. Cross-reac-
tivity between different allergens allows the repeated
stimulation and prolongs the lifetime of activated memory
cells. Furthermore as allergy is a chronic condition, allergic
patients have an increased risk for developing new sensi-
tizations. Total serum IgE concentration can stay within
normal range and none relationship between lgE and age or
age of onset of asthma has been established.19,20
The epithelial barrier is formed by the apical junction of
two adjacent ciliated cells called tight junctions (TJ). The
TJ control the intercellular transport of inhaled particles
and the flow of cell molecules occupying the intercellular
space within the epithelium. They are complex structures
composed of trans-membrane proteins and receptors such
asocludins, claudins, zonulaoccludensproteins 1e3 (ZO1e3),
E-cadherin and junctional adhesion molecules (JAM). The
intercellular adhesion is due to a structure known as the
adherence junction composed of the JAM and E-cadherin,
which is connected to E-cadherin of adjacent cells and
fixed to the cytoskeleton through protein molecules called
catenin. One of 3 the ways to the catenina, the bcateninas,
also participates in signaling internal chemical cell systems.
These molecules also facilitate communication between
adjacent cells.21,22
The most relevant allergens such as Der p 1 major
allergen, of Dermatophagoides pteronyssinus, are able to
modify the barrier function of the epithelium and activate
both the airway epithelial cells and cells in the immuno-
inflammatory system. Der p 1 has both cysteine and serine
protease activity that act enzymatically breaking the links
of occludin, claudins and zonula occludens (ZO) proteins
1e3, thus promoting access to the intraepithelial dendritic
cells.
Epithelial cells express poliovirus receptor-related
protein (PRR), toll like receptors (TLRs) and protease-
activated receptors (PARs), which recognize bacterial
agents and allergens. The microorganisms present small
molecular sequences designated (pathogen-associated
molecular patterns, or PAMPs) that are recognized by TLR
and the PRRS. The lipopolysaccaride (LPS) bacteria are
considered the prototype of PAMPs.
Recently, a new class of receptors for the recognition of
cytosol proteins nucleotide-binding oligomerization domain
(NOD) was identified, and recognized their involvement in
the intracellular activation after binding to PAR and TLR
expressed in epithelial cells. A cascade of intracellular
activation is triggered and neutrophils, monocytes and
dendritic cells’ chemoattractants and cytokines that lead
to their maturation are synthesized. These interactions will
also influence the intensity of the immune responses andthe polarization towards a Th1, Th2, Th17 or T regulatory
response.22,23 Although most of T lymphocytes participating
in asthma immune response are of the ab type there is
a small subset of pulmonary gd T cells involved in allergy
and in the defense against pathogens that can decrease
during the ageing process.24 This T cell subset can produce
high levels of IFN-g, which reduces IgE production. These
lymphocytes are reduced in elderly patients with long
lasting asthma and its reduction favors pulmonary
infection.25
A decrease in cells with a regulatory phenotype such as
Treg CD4hiCD25lo or a failure of Treg cells to give a posi-
tive response after contact with the allergen has been
found in patients with asthma and other allergic
diseases.26,27 On the contrary, the elderly population
seems to have an increase in these phenotypes with the
purpose of controlling the quiescent inflammation associ-
ated to the ageing process.28 These biological deviations
have a negative impact in clinical outcome of asthma in
the elderly.
In asthmatic patients, resistance of different inflam-
matory cells to initiate apoptosis has been observed, which
contributes to maintain ongoing cell activation in the
disease.29 Apoptosis is a classical way of depurating
dysfunctional cells and helps to keep tissue homeostasis.
Elevated levels of CD95 and higher sensitivity to apoptosis
induction seem to be a general feature of all cells in
elderly. Elderly asthmatic patients present reduced values
of CD95 and reduced susceptibility to start the apoptosis
process.30 This change can facilitate the development of
neoplasic diseases.
Many of the attacks to the airways are mediated by the
action of ROS. This cell damage may also be implicated in
other responses such as the induction of cell death,
apoptosis, or neoplastic transformation.
The epithelia damaged and the infiltrated inflammatory
cells lead to the generation of growth factors that interact
with the mesenchyme promoting airway remodeling and
a chronic and persistent inflammatory response.
Asthmatic airway walls present an accumulation of
activated eosinophils, lymphocytes, mast cells, macro-
phages, dendritic cells and myofibroblasts that together
determine the bronchial structural changes.31 Airway
remodeling with hypertrophy and hyperplasia of smooth
muscle, thickening of the reticular basement membrane
and modifications on the airway blood vessels can atten-
uate the load on airway smooth muscle that usually is
necessary during the respiratory circle to overcome the
lung elastic recoil force. On the other hand, the thickening
of the internal muscle wall can intensify airway smooth
muscle shortening and allows it to replace the scarce
elastic forces provided by lung recoil.32 In spite of the
apparent positive effect of airway remodeling in bronchi
functionality of elderly patients, these changes that are
linked to eosinophilic, lymphocytic and neutrophilic
inflammation should obviously be avoided and the tissue
integrity restored as much as possible.33,34
The inflammatory changes present in allergic rhinitis are
similar to those reported in asthma. The raise of total IgE
tends to be tapered and mast cells, eosinophils and
neutrophils have a primordial role in disease pathogeny and
evolution (Fig. 2).
Figure 2 Immuno-inflammatory changes in airways.
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The pathophysiology of allergic respiratory diseases is
multi-factorial and inflammatory mediators such as hista-
mine, leukotrienes, prostaglandins, and cytokines are
released in response to allergic and non-allergic triggers.
These mediators enter the peripheral blood and a systemic
inflammation becomes established. This sequence of
phenomena may increase the risk of cerebrovascular
thrombotic events. Allergic rhinitis and exposure of the
upper respiratory track to inflammatory triggers such as
infections, allergens and pollutants have been recognized
as an increased risk for stroke and for hospital admissions
caused by other vascular pathologies. Patients using anti-
histamines can be even at higher risk.35e37
Asthmatics have an increased susceptibility to athero-
sclerosis, which is probably connected with inflammatory
pathways inherent to both diseases. Cysteinyl leukotrienes
are potent inflammatory mediators implicated in the
pathogenesis of asthma and atherosclerosis.38 An associa-
tion between carotid intima-media thickness and adult-
onset asthma in women has been reported.39 Women with
late-onset of asthma have an increase incident of stroke
and coronary heart disease. Cyclic severity of asthma in
women is linked to changes in estrogens levels. Usually
uncontrolled asthma increases after puberty and after
menopause suggesting a hormonal modulation in the
disease severity and probably also in inflammatory cytokine
and leukotriene activities. Asthma is considered a risk
factor for the vascular disorders mentioned, independent
of smoking, body mass index, and physical activity.40,41
Asthma seems to increase atherosclerosis and both are
associated with cardiovascular disease.42,43Metabolic diseases such as diabetes can modify asthma
evolution. It has been observed that hyperglycemias are
associated with impaired lung function, and both hyper-
glycemias and asthma are associated with systemic
inflammation.44 A diet rich in fruits and vegetables is
associated with a decreased risk of newly diagnosed
asthma45 and COPD.46 The anti-inflammatory effects of U-3
fatty acids can modulate inflammatory activity and reduce
the risk of asthma and COPD.47,48 A study directed to
obstructive respiratory diseases and wheezing suggests that
U-3 fatty acid intake does not have the expected protective
effect on lung function or disease symptoms, but confirms
that U-6 acids can have adverse effects on lung function.49
Obesity is a metabolic or nutritional disturbance, which is
also considered a predisposing factor to have asthma,
mainly in women. Dyspnoea is a result of bronchocon-
striction and dynamic hyperinflation, which is amplified in
obese individuals. Symptoms and respiratory function tests
may be difficult to assess in obese asthmatic patients
because pulmonary dynamic is affected by a reduction in
chest wall compliance and by changes in the airway resis-
tance. The recognized reduction in static lung volumes,
particularly in functional residual capacity (FRC) and total
lung capacity (TLC) can be associated to a reduction also in
forced vital capacity (FVC) in severe obesity. These effects
of obesity on respiratory function may work in the opposite
direction from asthma, and can justify normal lung volume
measurements in obese individuals with asthma. Response
to bronchi provocation tests in obese individuals, shows an
increase in FRC and airtrapping and a reduction in inspira-
tory capacity (IC). Usually during bronchoconstriction,
there is an increase in the activity of the inspiratory
muscles to shorten the expiration and to maintain
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effect of fat on chest wall recoil.50e54 The increased risk for
asthma in obese is not a feature of elderly asthma but
affects all age groups.
Total Antioxidant Status (TAS) and SOD values are usually
higher in healthy individuals than in asthmatic patients.55
The reduction of the anti-oxidative capacity observed in
patients with long lasting asthma may have a negative
influence in other clinical conditions occurring in elderly.
Several studies have pointed out an association between
lung cancer and other pulmonary diseases such as bronchial
asthma, chronic bronchitis, emphysema and lung tubercu-
losis after adjustment for smoking habits. Increased risk of
developing lung cancer has been reported in individuals
with cough, dyspnoea and effort dyspnoea in both genders.
The risk increases with the number of symptoms reported,
mainly for non-small cell lung cancer.
It is anticipated that chronic inflammatory process and
reduced apoptosis may stimulate local cell-proliferation
and growth, favoring malignant pulmonary diseases. Trying
to modulate pulmonary inflammation may help to prevent
later development of lung cancer.56e60
Pneumonia and influenza infection have long been
considered one of the most common health problems of old
people. The infection causes inflammation, deterioration of
lung function and reduction of oxygen blood transfer
increasing breathing effort. Older people have weakened
defenses against infection. Cough is not as effective as in
younger people. Elderly populations whose lungs have been
damaged by chronic obstructive pulmonary disease develop
repeated infections and severe dyspnoea attacks.Therapeutic and ageing conditionings
Older patients with multiple morbidities may have an
aversion to taking multiple drugs, mainly those that should
be taken regularly. They usually prefer drugs that can be
adjusted to their symptoms. The cost of the medication
may also be a limitation for adhesion to treatment. Older
people may also assess differently their symptoms of
asthma since they consider dyspnoea a less bothersome
symptom than younger patients.61 Drugs without recog-
nized clinical benefit should be withdrawn.
The initial approach to treat allergic diseases starts with
an accurate identification of triggers to avoid the offender
antigens when possible and to reduce medication needs.
Patients should also be advised to avoid non-allergic factors
which may induce their respiratory symptoms, including
irritants as cigarette smoke and household aerosols.
Patient’s medication list should be analyzed to detect any
medications that can exacerbate asthma, such as beta-
blocker eye drops and anti-hypertensive therapy.
Controller medications are indicated if rescue medica-
tions are often required (more than twice a week).
Corticosteroids dampen the inflammatory reaction
characteristic of allergy; therefore they are the first choice
treatment for long-term in patients with persistent asthma
and persistent rhinitis. Untreated chronic airway inflam-
mation may produce structural changes in the airways and
fixed obstruction. This is pertinent, because most of the
elderly patients that are hospitalized for asthma were notusing any controller medication in the year preceding the
asthma exacerbation.62,63
Inhaled corticosteroids can produce good effects at low
doses having few systemic adverse effects and being safe in
the elderly. Low doses of inhaled steroids demonstrate
significant change in airway mucosal inflammation. To
reduce the basement membrane thickness in asthmatic
patients, the use of higher doses of inhaled steroids is
determinant but this approach is more important in the
initial phases of the disease.64 However, cognitive and
sensory impairment compounds and also co-morbidities
such as rheumatoid diseases can affect self-handling of
inhaler devices. Dry powder inhalers require appropriate
inspiratory flow, which excludes their administration to
some patients. The most convenient inhaler device for an
old person is a spacer with a metered dose inhaler. The
compliance to the different types of aerosol should be
considered in elderly patients. Their use can be associated
to local adverse reactions such as oropharyngeal candidiasis
and hoarseness, which can be prevented by using a spacer
or by rinsing the mouth after use. If patients receive very
high doses of ICS, they have potential for systemic
absorption, with suppression of hypothalamus, pituitary
and adrenal function and side effects similar to those
receiving low doses of oral corticosteroids. As a conse-
quence they can also develop cataracts, glaucoma and
osteoporosis. Oral steroids can be used in more severe
conditions for short periods of time.
Nasal corticosteroids are the first line of medical therapy
for allergic rhinitis since they rarely produce serious side
effects and they are effective in all forms of rhinitis.
Elderly patients treated with high doses of corticoste-
roids should be regularly submitted to bone density
measurements to evaluate osteoporosis and the risk of bone
fractures. Exercise should be encouraged and supplements
of oral calcium with vitamin D should be considered.
Ophthalmologic examination to check vision, slit lamp
exams to look for cataract and intraocular pressure testing
are also recommended. To follow blood glucose levels are
recommended for known diabetics and blood pressure
measurement should be performed in each visit.
To reduce the dose of ICS or the need for oral steroids,
steroid-sparing medications such as leukotriene receptor
antagonists and long-acting beta-agonists may be added.
Oral leukotriene antagonists are CysLT1 receptor
antagonists that provide rapid improvement of respiratory
function. They are safe but liver damage has been observed
in a little number of cases.
The b2 agonists are drugs that relax smooth muscle and
promote the removal of airways secretions by ciliar move-
ment. The formulations of long-term b2 agonists are used
as controller medications in asthma. While long-acting
beta-agonists currently available are safe, they should be
used with caution in patients with cardiac disease. The
density of b2-receptors decreases with age and conse-
quently the b2 agonists may be less effective in elderly
patients with asthma.
Short-acting b2 agonists are relatively safe in the elderly
if used as rescue medication to revert exacerbations.
Although systemic absorption can produce tachycardia,
palpitations and tremor they are less common with inhaled
formulations. Both short-acting and long-acting b2 agonists
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and diabetes. Overdose may cause hypokalemia and
arrhythmia.
An alternative rescue medication to short-acting b2
agonist is ipratropium bromide. Anticholinergic agents are
useful alternative, particularly in the case of partial
relaxant effects and when an adverse effect upon admin-
istration of b2-mimetics occurs.65
Allergen immunotherapy should be reserved for patients
whose medical approach of allergic rhinosinusitis or asthma
fails. Although effective in younger patients, has a ques-
tionable efficacy in elderly and is not without risk. Adverse
reactions range from local irritation till anaphylaxis and
epinephrine therapy for rescue may be ineffective or
associated with acute hypertension. Immunotherapy is also
contraindicated in patients with persistent severe asthma
where adverse respiratory reactions may be difficult to
treat.
Although most of the effects of histamine in allergic
disease occur through histamine-1 (H1) receptors, hypo-
tension, tachycardia, flushing and headache occur through
both the H1 and H2 vascular receptors, whereas cutaneous
itch and nasal congestion may occur through the H1 and H3
receptors. In addition to its role in the early allergic
response to antigen, histamine acts as a stimulatory signal
for the production of cytokines and the expression of cell-
adhesion molecules and class II antigens, thereby contrib-
uting to the late allergic response. Histamine exerts other
important immunomodulatory effects through H1, H2, H3,
and H4 receptors. The four major types of histamine
receptor differ in their expression, signal transduction, and
function. H1 and H2 receptors are widely expressed, in
contrast to H3 and H4 receptors. Antihistamines block the
effects of histamine, the main mediator of the immune
system in a type I allergic reaction and is recommended in
all forms of rhinitis and allergic diseases. They are associ-
ated with adverse effects such as drowsiness or malaise so
their use in elderly patients should be carefully evaluated.
The first generation of H1 receptor antagonists should be
avoided as they lack specificity for the H1 receptor and
produce a variety of side effects in elderly, including
anxiety, confusion, sedation, disequilibrium, postural
hypotension, constipation and urinary retention. The
second generation of H1 receptor antagonists has reduced
side effects, low cross blood brain barrier and greater
specificity for its receptor.
All the first-generation H1-antihistamines and some
second-generation H1-antihistamines such as desloratadine
and loratadine are metabolized by the system cytochrome
P450 hepatic. Cetirizine is excreted largely unchanged in
the urine, and fexofenadine is excreted largely unchanged
in the feces. Interactions that result in changes in plasma
concentrations can diminish or increase adverse effects.
Interactions may be more likely to be associated with first-
generation H1-antihistamines than second-generation H1-
antihistamines, which have a wider therapeutic index.
Theophylline has a narrow therapeutic window and is
not considered the first choice medication in the elderly.
Nevertheless theophilin is less expensive than other ther-
apeutic drugs for asthma and in low blood concentration
have anti-inflammmatory effects.66 Adenosine is a biolog-
ical mediator with the capacity of producing proinflammatory effects in part through A(2B) adenosine
receptors response of mast cells, epithelial cells and
smooth muscle cells. Theophilin can act as both broncho-
dilator and immunomodulator depending on the serum
concentration achieved. The antagonism of adenosine
receptors occurs in lower dose than that required for inhi-
bition of phosphodiesterases. Accordingly theophyline is
safe if properly used and should be reconsidered in asthma
treatment in all aged groups.67,68
Influenza vaccine should be administered annually to
prevent old patients from getting influenza and is especially
recommended if they have a chronic medical problem, such
as asthma. Effectiveness of routine use of pneumococcal
vaccine in people with asthma is still controversial even in
elderly.69
Other therapeutic alternatives such as thromboxane A2
antagonists or even cytokine inhibitors should be consid-
ered in particular cases.
Elderly usually have difficulties to access to health
services. The asthmatic patients should be educated about
their disease and receive a written treatment plan. This
plan is a guide with information about controller and
reliever medication and should also be explained to family
members. Patients should be able to recognize an asthma
exacerbation and what to do to reverse it. This information
improves the quality of life, socialization and hobbies
throughout the ageing process.
Conclusion
It is important to recognize that allergic respiratory
diseases often start during childhood but they can last for
life. New sensitizations may occur at any age and elderly
people have a higher risk of having multiple allergy
syndrome. The local inflammatory disabilities can produce
structural changes in the airways and when extended
systemic immune-inflammatory deviations can be
observed. An aggressive therapeutic approach should be
implemented in early states of the disease to minimize
these changes. In elderly a more conservative therapy
should be selected, but the control of inflammation has to
be assured. It is important to assure respiratory function
and also to reduce asthma-associated respiratory diseases.
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